The activity of silver nanoparticles (Axonnite) on clinical and environmental strains of Acinetobacter spp.

Burns

Volumn 41, Issue 2, 2015, Pages 364-371

  Łysakowska, Monika E ^a   Ciebiada Adamiec, Anna ^b   Klimek, Leszek ^a,c   Sienkiewicz, Monika ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^c LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Acinetobacter baumannii; AgNPs; Silver nanoparticles

Indexed keywords

AMIKACIN; AXONNITE; AZTREONAM; CEFEPIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SILVER NANOPARTICLE; SULFAMETHOXAZOLE; SULTAMICILLIN; TOBRAMYCIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; METAL NANOPARTICLE; SILVER;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER NOSOCOMIALIS; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISK DIFFUSION; MICROBIOLOGICAL EXAMINATION; MICRODILUTION METHOD; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ACINETOBACTER INFECTIONS; CHEMISTRY; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; METAL NANOPARTICLES; MICROBIAL SENSITIVITY TESTS; SILVER;

EID: 84923047929     PISSN: 03054179     EISSN: 18791409     Source Type: Journal    
DOI: 10.1016/j.burns.2014.07.014     Document Type: Article

References (64)

1. Huang L, Dai T, Xuan Y, Tegos GP, Hamblin MR. Synergistic combination of chitosan acetate with nanoparticle silver as a topical antimicrobial: efficacy against bacterial burn infections. Antimicrob Agents Chemother 2011;55:3432-8.
2. Karakoc C, Tekin R, Yesilbag Z, Cagatay A. Risk factors for mortality in patients with nosocomial Gram-negative rod bacteremia. Eur Rev Med Pharmacol Sci 2013;17:951-7.
3. Alp E, Coruh A, Gunay GK, Yontar Y, Doganay M. Risk factors for nosocomial infection and mortality in burn patients: 10 years of experience at a university hospital. J Burn Care Res 2012;33:379-85.
4. Bayram Y, Parlak M, Aypak C, Bayram I. Three-year review of bacteriological profile and antibiogram of burn wound isolates in Van, Turkey. Int J Med Sci 2013;10:19-23.
5. Marti S, Chabane YN, Alexandre S, Coquet L, Vila J, Jouenne T, et al. Growth of Acinetobacter baumannii in pellicle enhanced the expression of potential virulence factors. PLoS ONE 2011. http://dx.doi.org/10.1371/journal.pone.0026030.
6. Wisplinghoff H, Perbix W, Seifert H. Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis 1999;28:59-66.
7. Barnaud G, Zihoune N, Ricard JD, Hippeaux MC, Eveillard M, Dreyfuss D, et al. Two sequential outbreaks caused by multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 or OXA-72 oxacillinase in an intensive care unit in France. J Hosp Infect 2010;76:358-60.
8. Morgan DJ, Liang SY, Smith CL, Johnson JK, Harris AD, Furuno JP, et al. Frequent multidrug-resistant Acinetobacter baumannii contamination of gloves, gowns, and hands of healthcare workers. Infect Control Hosp Epidemiol 2010;31:716-21.
9. Nseir S, Blazejewski C, Lubret R, Wallet F, Courcol R, Durocher A. Risk of acquiring multidrug-resistant Gramnegative bacilli from prior room occupants in the intensive care unit. Clin Microbiol Infect 2011;17:1201-8.
10. Kempf M, Rolain JM, Azza S, Diene S, Joly-Guillou ML, Dubourg G, et al. Investigation of Acinetobacter baumannii resistance to carbapenems in Marseille hospitals, south of France: a transition from an epidemic to an endemic situation. APMIS 2013;121:64-71.
11. Biglari S, Hanafiah A, Ramli R, Mostafizur Rahman M, Mohd Nizam Khaithir T. Clinico-epidemiological nature and antibiotic susceptibility profile of Acinetobacter species. Pak J Med Sci 2013;29:469-73.
12. Manian FA, Griesenauer S, Senkel D, Setzer JM, Doll SA, Perry AM, et al. Isolation of Acinetobacter baumannii complex and methicillin-resistant Staphylococcus aureus from hospital rooms following terminal cleaning and disinfection: can we do better. Infect Control Hosp Epidemiol 2011;32:667-72.
13. Barbut F, Yezli S, Mimoun M, Pham J, Chaouat M, Otter JA. Reducing the spread of Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus on a burns unit through the intervention of an infection control bundle. Burns 2013;39:395-403.
14. Ray A, Perez F, Beltramini AM, Jakubowycz M, Dimick P, Jacobs MR, et al. Use of vaporized hydrogen peroxide decontamination during an outbreak of multidrugresistant Acinetobacter baumannii infection at a long-term acute care hospital. Infect Control Hosp Epidemiol 2010;31:1236-41.
15. Cheng L, Weir MD, Xu HHK, Antonucci JM, Kraigsley AM, Lin NJ, et al. Antibacterial amorphous calcium phosphate nanocomposites with a quaternary ammonium dimethacrylate and silver nanoparticles. Dent Mater 2012;28:561-72.
16. Fong J, Wood F, Fowler B. A silver coated dressing reduces the incidence of early burn wound cellulites and associated costs of inpatient treatment: comparative patient care audits. Burns 2005;31:562-7.
17. Gordon O, Slenters TV, Brunetto PS, Villaruz AE, Sturdevant DE, Otto M, et al. Silver coordination polymers for prevention of implant infection: thiol interaction, impact on respiratory chain enzymes, and hydroxyl radical induction. Antimicrob Agents Chemother 2010;54:4208-18.
18. Rigo R, Ferroni L, Tocco I, Roman M, Munivrana I, Gardin C, et al. Active silver nanoparticles for wound healing. Int J Mol Sci 2013;14:4817-40.
19. Tian J, Wong KK, Ho CM, Lok CN, Yu WY, Che CM, et al. Topical delivery of silver nanoparticles promotes wound healing. Chem Med Chem 2007;2:129-36.
20. Rai MK, Deshmukh SD, Ingle AP, Gade AK. Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria. J Appl Microbiol 2012;112:841-52.
21. Boonkaew B, Kempf M, Kimble R, Supaphol P, Cuttle L. Antimicrobial efficacy of a novel silver hydrogel dressing compared to two common silver burn wound dressings: Acticoat™ and PolyMem Silver®. Burns 2014;40:89-96.
22. Chamakura K, Perez-Ballestrero R, Luo Z, Bashir S, Liu J. Comparison of bactericidal activities of silver nanoparticles with common chemical disinfectants. Colloids Surf B 2011;84:88-96.
23. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Ramirez JT, et al. The bactericidal effect of silver nanoparticles. Nanotechnology 2005;16:2346-53.
24. Dror-Ehre A, Mamane H, Belenkova T, Markovich G, Adin A. Silver nanoparticle - E. coli colloidal interaction in water and effect on E. coli survival. J Colloids Interface Sci 2009;339:521-6.
25. Wu J, Hou SY, Ren DC, Mather PT. Antimicrobial properties of nanostructured hydrogel webs containing silver. Biomacromolecules 2009;10:2686-93.
26. Taglietti A, Diaz Fernandez YA, Amato E, Cucca L, Dacarro G, Grisoli P, et al. Antibacterial activity of glutathione-coated silver nanoparticles against Gram positive and Gram negative bacteria. Langmuir 2012;28:8140-8.
27. Yamanaka M, Hara K, Kudo J. Bactericidal actions of a silver ion solution on Escherichia coli, studied by energy-filtering transmission electron microscopy and proteomic analysis. Appl Environ Microbiol 2005;71:7589-93.
28. Bragg PD, Rainnie DJ. The effect of silver ions on the respiratory chain of Escherichia coli. Can J Microbiol 1974;20:883-9.
29. Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection control and healing: review of the literature. Burns 2007;33:139-48.
30. Panáček A, Kolář M, Večeřová R, Prucek R, Soukupová J, Krystof V, et al. Antifungal activity of silver nanoparticles against Candida spp.. Biomaterials 2009;30:6333-40.
31. Percival SL, Thomas J, Linton S, Okel T, Corum L, Slone W. The antimicrobial efficacy of silver on antibiotic-resistant bacteria isolated from burn wounds. Int Wound J 2012;9:488-93.
32. Wataha JC, Lockwood PE, Schedle A. Effect of silver, copper, mercury, and nickel ions on cellular proliferation during extended, low-dose exposures. J Biomed Mater Res 2000;52:360-4.
33. Wataha JC, Lockwood PE, Schedle A, Noda M, Bouillaguet S. Ag, Cu, Hg and Ni ions alter the metabolism of human monocytes during extended low-dose exposures. J Oral Rehabil 2002;29:133-9.
34. Arora S, Jain J, Rajwade JM, Paknikar KM. Interactions of silver nanoparticles with primary mouse fibroblasts and liver cells. Toxicol Appl Pharmacol 2009;236:310-8.
35. Jain J, Arora S, Rajwade J, Khandelwal S, Paknikar KM. Silver nanoparticles in therapeutics: development of an antimicrobial gel formulation for topical use. Mol Pharm 2009;6:1388-401.
36. Wei L, Tang J, Zhang Z, Chen Y, Zhou G, Xi T. Investigation of the cytotoxicity mechanism of silver nanoparticles in vitro. Biomed Mater 2010;5:044103.
37. Zanette C, Pelin M, Crosera M, Adami G, Bovenzi M, Larese FF, et al. Silver nanoparticles exert a long-lasting antiproliferative effect on human keratinocyte HaCaT cell line. Toxicol In Vitro 2011;25:1053-60.
38. Moiemen NS, Shale E, Drysdale KJ, Smith G, Wilson YT, Papini R. Acticoat dressings and major burns: systemic silver absorption. Burns 2011;37:27-35.
39. Wang XQ, Chang HE, Francis R, Olszowy H, Liu PY, Kempf M, et al. Silver deposits in cutaneous burn scar tissue is a common phenomenon following application of a silver dressing. J Cutan Pathol 2009;36:788-92.
40. Nikaido H. Prevention of drug access to bacterial targets: role of permeability barrier and active efflux. Science 1994;264:382-8.
41. Silver S, Phung LT. Bacterial heavy metal resistance mechanisms: new surprises. Annu Rev Microbiol 1996;50:753-89.
42. Pugsley AP, Schnaitman CA. Outer membrane proteins of Escherichia coli. VII. Evidence that bacteriophage-directed protein 2 functions as a pore. J Bacteriol 1978;133:1181-9.
43. + and are deficient in porins. J Bacteriol 1997;179:6127-32.
44. Deshpande LM, Chopade BA. Plasmid mediated silver resistance in Acinetobacter baumannii. BioMetals 1994;7:49-56.
45. Mendez JA, Soares NC, Mateos J, Gayoso C, Rumbo C, Aranda J, et al. Extracellular proteome of a highly invasive multidrug-resistant clinical strain of Acinetobacter baumannii. J Proteome Res 2012;11:5678-94.
46. Siroy A, Cosette P, Seyer D, Lemaître-Guillier C, Vallenet D, Van Dorsselaer A, et al. Global comparison of the membrane subproteomes between a multidrug-resistant Acinetobacter baumannii strain and a reference strain. J Proteome Res 2006;5:3385-98.
47. Fernández-Reyes M, Rodríguez-Falcón M, Chiva C, Pachón J, Andreu D, Rivas L. The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. Proteomics 2009;9:1632-45.
48. Chopra S, Ramkissoon K, Anderson DC. A systematic quantitative proteomic examination of multidrug resistance in Acinetobacter baumannii. J Proteomics 2013;84:17-39.
49. Higgins PG, Wisplinghoff H, Krut O, Seifert H. A PCR-based method to differentiate between Acinetobacter baumannii and Acinetobacter genomic species 13TU. Clin Microbiol Infect 2007;13:1199-201.
50. Polish Pharmacopoeia VI. 6th ed. Warsaw: Polish Pharmaceutical Society; 2002.
51. Łysakowska ME, Denys A, Klimek L, Ciebiada-Adamiec A, Sienkiewicz M. The activity of silver nanoparticles (Axonnite) on clinical and environmental strains of Enterococcus spp.. Microb Drug Resist 2013;19:21-9.
52. Clinical and Laboratory Standard Institute (CLSI). Performance standards for antimicrobial susceptibility testing: nineteenth informational supplement. CLSI document M100-S19. 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 U.S.A.: Clinical and Laboratory Standards Institute; 2009.
53. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692-9.
54. Qi C, Scheetz MH, Malczynski M. Characterization of Acinetobacter baumannii genotypes recovered from patients with repeated colonization or infection. Diagn Microbiol Infect Dis 2009;65:1-6.
55. Herruzo R, de la Cruz J, Fernández-Aceñero MJ, Garcia-Caballero J. Two consecutive outbreaks of Acinetobacter baumanii 1-a in a burn Intensive Care Unit for adults. Burns 2004;30:419-23.
56. Manchanda V, Sanchaita S, Singh N. Multidrug resistant Acinetobacter. J Glob Infect Dis 2010;2:291-304.
57. Kouyama Y, Harada S, Ishii Y, Saga T, Yoshizumi A, Tateda K, et al. Molecular characterization of carbapenem-non-susceptible Acinetobacter spp. in Japan: predominance of multidrug-resistant Acinetobacter baumannii clonal complex 92 and IMP-type metallo- b-lactamase-producing non-baumannii Acinetobacter species. J Infect Chemother 2012;18:522-8.
58. Wisplinghoff H, Paulus T, Lugenheim M, Stefanik D, Higgins PG, Edmond MB, et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect 2012;64:282-90.
59. Kong H, Jang J. Antibacterial properties of novel poly(methyl methacrylate) nanofiber containing silver nanoparticles. Langmuir 2008;24:2051-6.
60. Fuller FW. The side effects of silver sulfadiazine. J Burn Care Res 2009;30:464-70.
61. Sintubin L, De Windt W, Dick J, Mast J, van der Ha D, Verstraete W, et al. Lactic acid bacteria as reducing and capping agent for the fast and efficient production of silver nanoparticles. Appl Microbiol Biotechnol 2009;84:741-9.
62. Sarkar S, Jana AD, Samanta SK, Mostafa G. Facile synthesis of silver nanoparticles with highly efficient anti-microbial property. Polyhedron 2007;26:4419-26.
63. Hernández-Sierra JF, Ruiz F, Pena DC, Martínez-Gutiérrez F, Martínez AE, Guillén Ade J, et al. The antimicrobial sensitivity of Streptococcus mutans to nanoparticles of silver, zinc oxide, and gold. Nanomedicine 2008;4: 237-40.
64. Egger S, Lehmann RP, Height MJ, Loessner MJ, Schuppler M. Antimicrobial properties of a novel silver-silica nanocomposite material. Appl Environ Microbiol 2009;75:2973-6.